Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lyell Immunopharma Inc | LYEL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.36 | 03:08:22 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.36 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.32 - 3.97 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.36 | USD |
Lyell Immunopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 599.67M | 254.10M | - | 2.92M | -234.63M | -0.92 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lyell Immunopharma News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LYEL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.19 | 2.66 | 2.14 | 2.31 | 609,150 | 0.17 | 7.76% |
| 1 Month | 2.12 | 3.145 | 2.06 | 2.46 | 963,642 | 0.24 | 11.32% |
| 3 Months | 1.82 | 3.2556 | 1.73 | 2.34 | 902,550 | 0.54 | 29.67% |
| 6 Months | 2.14 | 3.2556 | 1.525 | 2.11 | 1,119,586 | 0.22 | 10.28% |
| 1 Year | 2.48 | 3.97 | 1.32 | 2.32 | 1,013,709 | -0.12 | -4.84% |
| 3 Years | 18.75 | 19.84 | 1.32 | 4.78 | 938,832 | -16.39 | -87.41% |
| 5 Years | 18.75 | 19.84 | 1.32 | 4.78 | 938,832 | -16.39 | -87.41% |
Lyell Immunopharma Description
| Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). |
